Arbutus Biopharma to present liver disease data

Accepted by SEC EDGAR 10/07/2025 - 08:01 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Arbutus Biopharma Corporation reported that three abstracts featuring imdusiran data and one abstract featuring AB-101 data have been accepted for poster presentations at the American Association for the Study of Liver Diseases – The Liver Meeting® 2025 in Washington, DC. The meeting is scheduled for November 7–11, 2025.

The company noted that the AB-101 abstract has been selected as a Poster of Distinction, highlighting it among the conference’s poster presentations. These details were originally shared in a press release dated October 7, 2025, which is attached as an exhibit.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Arbutus Biopharma (ABUS) announce in this 8-K filing?

Arbutus Biopharma announced that three abstracts featuring imdusiran data and one abstract featuring AB-101 data were accepted for poster presentations at The Liver Meeting® 2025.

Which conference will feature Arbutus Biopharma’s imdusiran and AB-101 data?

The data will be presented at the American Association for the Study of Liver Diseases – The Liver Meeting® 2025, taking place in Washington, DC.

When is The Liver Meeting® 2025 where Arbutus Biopharma will present?

The Liver Meeting® 2025 is scheduled for November 7–11, 2025, in Washington, DC.

What special recognition did Arbutus Biopharma’s AB-101 abstract receive?

The abstract featuring AB-101 data was selected as a Poster of Distinction at The Liver Meeting® 2025.

How did Arbutus Biopharma initially communicate this conference news?

The company issued a press release dated October 7, 2025, which is attached to the report as Exhibit 99.1 and incorporated by reference.

Which drug candidates from Arbutus Biopharma are mentioned in this filing?

The filing mentions imdusiran and AB-101, each featured in abstracts accepted for poster presentations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

False000144702800014470282025-10-072025-10-07iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  October 7, 2025

_______________________________

Arbutus Biopharma Corporation

(Exact name of registrant as specified in its charter)

_______________________________

British Columbia, Canada	001-34949	98-0597776
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

701 Veterans Circle

Warminster, Pennsylvania 18974

(Address of Principal Executive Offices) (Zip Code)

(267) 469-0914

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, without par value	ABUS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On October 7, 2025, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing that three abstracts featuring imdusiran data and one abstract featuring AB-101 data, have been accepted for poster presentations at the American Association for the Study of Liver Diseases – The Liver Meeting® 2025, taking place November 7–11, 2025 in Washington, DC. The AB-101 abstract has been selected as a Poster of Distinction. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release dated October 7, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Arbutus Biopharma Corporation
Date: October 7, 2025	By:	/s/ Tuan Nguyen
		Tuan Nguyen
		Chief Financial Officer